• Ethan O Bryson, Gabriella M Ahle, Lauren S Liebman, Amy S Aloysi, Matthew F Majeske, Kyle A Lapidus, and Charles H Kellner.
• Associate Professor, Departments of Anesthesiology and Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• Australas Psychiatry. 2014 Oct 1; 22 (5): 467-9.

ObjectiveTo provide additional data about the clinical efficacy and dosing range for ketamine used as the induction agent in electroconvulsive therapy (ECT).MethodWe reviewed the clinical data in our academic hospital ECT service over the last four years for patients who had received ketamine as the sole, or adjunctive, anesthesia induction agent. We extracted clinical data about antidepressant response as well as absolute and weight-based dosing for ketamine.ResultsWe found nine patients who were treated with ketamine as the anesthetic at some point during the course of their treatment (eight as the sole agent, one as adjunctive). The median induction dose for ketamine was 1.1 mg/kg. For most patients, there was demonstrable clinical benefit.ConclusionsKetamine has a role as an alternative induction anesthetic agent in ECT. Our case series adds to the literature on the concomitant use of ECT and ketamine.© The Royal Australian and New Zealand College of Psychiatrists 2014.

19 keywords...

hide…